IMPACT OF EJECTION FRACTION ON SURVIVAL BENEFIT WITH IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR THERAPY  by Issa, Meltiady et al.
E37
JACC April 5, 2011
Volume 57, Issue 14
   CARDIAC ARRHYTHMIAS 
IMPACT OF EJECTION FRACTION ON SURVIVAL BENEFIT WITH IMPLANTABLE CARDIOVERTER-
DEFIBRILLATOR THERAPY
ACC Poster Contributions
Ernest N. Morial Convention Center, Hall F
Sunday, April 03, 2011, 10:00 a.m.-11:15 a.m.
Session Title: Outcomes in ICD Therapy
Abstract Category: 29. Defibrillation/Implantable Antiarrhythmia Devices
Session-Poster Board Number: 1022-388 
Authors: Meltiady Issa, Ilke Sipahi, Sunit - Preet Chaudhry, James C. Fang, Marshfield Clinic, Marshfield, WI, University Hospitals Case Medical 
Center, Cleveland, OH
Background:  For primary prevention of sudden cardiac death (SCD), the survival benefit of implantable cardioverter-defibrillator (ICD) therapy 
has been suggested to be limited to patients with severe left ventricular systolic dysfunction. This observation was made on the basis of subgroup 
analysis within 2 large ICD trials. There is no systematic analysis that examines whether the magnitude of benefit is related to the degree of left 
ventricular dysfunction.
Methods:  A systematic literature search of SCOPUS including MEDLINE and EMBASE was conducted for randomized controlled clinical trials (RCTs) 
involving ICD. Primary prevention trials reporting all-cause mortality according to different ejection fraction (EF) subgroups were included. Fixed 
effect models were used to obtain meta-analytic hazard ratios and 95% confidence intervals (CI) for all-cause mortality.
Results:  A total of 5 RCTs enrolling 4236 patients (2227 ICD, 2009 control) were included. Patients with severely reduced EF (<20-30%, n= 2648) 
had a significant decrease in all-cause mortality (HR=0.71 [95% CI: 0.61-0.83], p=0.00002). There was a similar decrease in all-cause mortality 
in patients with moderately reduced EF (>20-30%, n=1416) (HR 0.73 [95%CI: 0.55-0.95], p=0.02). The magnitude of benefit with ICD was not 
significantly different between the two EF groups (p=0.90).
Conclusion: The magnitude of benefit with ICD therapy for the primary prevention of SCD is not different in patients with moderately vs. severely 
reduced EF. 
